Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback